Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2505713 | 0.65 | LMNA (0.32) | OR51E2 | |
| SCHEMBL765239 | 0.64 | — | — | |
| SCHEMBL12179455 | 0.64 | — | — | |
| SCHEMBL8866832 | 0.62 | OR51E2 (0.47) | OR51E2 | |
| SCHEMBL2497721 | 0.61 | UHRF1 (0.34) | — | |
| SCHEMBL12498079 | 0.60 | OR51E2 (0.31) | OR51E2 | |
| SCHEMBL2497719 | 0.58 | OR51E2 (0.30) | OR51E2 | |
| SCHEMBL3694424 | 0.58 | PNMT (0.30) | — | |
| SCHEMBL3694516 | 0.58 | PNMT (0.30) | — | |
| SCHEMBL11983397 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010077740-A2 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| US-10479794-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-11-19 | — | — | US | disclosed |
| US-20180134720-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2018-05-17 | — | — | US | disclosed |
| WO-2010077740-A2 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479794-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | CNP, PDE5A, PDE3A | OR51E2 3367/4885 |
| US-20180134720-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | CNP, PDE5A, PDE3A | OR51E2 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.